Therapeutic Nuclear Medicine Market Growth Opportunities: 2034

Therapeutic Nuclear Medicine Market Outlook for 2024 to 2034

The therapeutic nuclear medicine market is foreseen to register a CAGR of 4.10% from 2024 to 2034, with a market valuation of US$ 1.32 billion in 2024. Developing demand is invoked to set a valuation of US$ 1.97 billion in 2034 for the market.

Attributes	Details
Market Value for 2024	US$ 1.32 billion
Market Value for 2034	US$ 1.97 billion
Market Forecast CAGR for 2024 to 2034	4.10%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Consumption Analysis of Therapeutic Nuclear Medicines

Demand for therapeutic nuclear medicine is emerging as the incidence of cancers, bone deformities, and neurological malignancies rises in developing nations.
Development in diagnosis technology encouraging the use of radiopharmaceuticals to diagnose and treat cancerous tumors contributes to the evolution of the market.
Demand for nuclear medicines is experiencing evolution due to a vigorous product pipeline and promising government endeavors to enhance access to nuclear medication.
Awareness and utility of radioisotopes in nuclear medicine therapeutics propose novel prospects for research and development, thereby propelling market growth in the forthcoming decade.
Market value is lowering due to radiation safety concerns, contamination, and the brief half-life of radionuclides.

Historical Performance and Future Growth of the Therapeutic Nuclear Medicine Market

The historical CAGR of 11.70% was recorded for the market and a 4.10% CAGR is calculated through 2034. The market is evolving with the introduction of the product in palliative therapy, taking advantage of the lack of response to different treatments for distressing bone metastasis.

Attributes	Details
Historical CAGR for 2019 to 2023	11.70%

Acute aspects that are anticipated to influence the demand for the product through 2034 include:

Prevalence of cancers, bone deformities, and neurological malignancies develops research opportunities related to nuclear medicine.
Global establishments are anticipated to diminish chronic diseases at their initial stages, thus limiting the need for the treatment in the forthcoming decade.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Key Trends Influencing the Therapeutic Nuclear Medicine Market

Cancer and Cardiovascular Diseases See Stakes Rise in the Demand for the Market

Prevalence of cancers and cardiovascular diseases is primarily propelling the market.
The American Cancer Society reported in 2022, around 268,490 prostate cancer cases and approximately 34,500 deaths, with 6 out of 10 diagnosed being men over 65 and rare in those under 40. Therapeutic nuclear medication is envisioned to significantly contribute to diagnosing and treating cancers and cardiovascular diseases in the forthcoming decade.

The Geriatric Population Demands Innovation in the Industry

Global geriatric population is experiencing a surge in cardiovascular diseases, leading to a significant demand for innovation in nuclear medicines.
Upsurge in cancer patients above 65 necessitates the application of the medicine for detection and treatment, making this vital for geriatric health.
Geriatric patients are anticipated to have low immunity to cardiovascular diseases, leading to an advanced consumer base for therapeutic nuclear medication and treatment.

Establishments Perform Novel Research and Development in Therapeutic Nuclear Medicine

Establishments such as hospitals and research institutes globally focus on developing nuclear medicine therapies due to their superior clinical effects compared to other treatments. For instance, FUJIFILM Toyama Chemical Co., Ltd. launched Lutathera injection in August 2021, a therapeutic medication targeting neuroendocrine tumors.
Novel nuclear medicines have seen greater demand among patients and physicians, enabling pharmaceutical manufacturers to develop more efficient treatments.
Demand for nuclear medicine therapies in countries with high cancer burdens is divined to advance due to improvements in therapeutic applications and outcomes.

Category-wise Insights

The following part offers an in-depth segmental analysis of the therapeutic nuclear medicine market. The demand for Radium-223 is significant, whereas the demand for prostate cancer treatment is anticipated to be augmented in 2024.

Radium-223 Captures Around 77.5% of Market Share

Attributes	Details
Top Radionuclide Type	Radium-223
Market share in 2024	77.50%

The demand for Radium-223 is significant, slotted in to acquire a market share of 77.5% in 2024. The following aspects aid the development of demand for Radium-223:

Researchers are exploring the potential of Radium-223, a small molecule, to treat advanced prostate cancer and induce immune changes earlier in the disease, using radiation to kill cancer cells.
In May 2013, the United States Food and Drug Administration (FDA) approved radium Ra 223 dichloride to treat tumors.
The demand for Radium-223 is significant as it is utilized in cancer therapy through sealed and unsealed sources, to inhibit tumor growth.

Prostate Cancer Accounts for 55.6% of Market Share

Attributes	Details
Top Indication	Prostate Cancer
Market share in 2024	55.60%

Prostate cancer is penned in to acquire a market share by indication of 55.6% in 2024. The following aspects aid the development of the medicines in prostate cancer treatment:

Scientists are studying the treatment for prostate cancer, and so far, they have established several nuclear medicines that are likely to aid in cancer recovery.
In December 2020, the United States Food and Drug Administration approved Gallium 68 PSMA-11, the medicine for PET imaging to diagnose prostate cancer.

Country-wise Insights

According to derived data, the demand from European countries is supposed to augment the sales growth of the medicines in the forthcoming decade. The industry in France and Germany is developing steeply. The therapeutic nuclear medication industry in the United Kingdom is anticipated to register a subordinate CAGR compared to other European nations. The demand for treatment is developing rapidly in Italy and Russia.

Countries	CAGR from 2024 to 2034
Russia	6.4%
Germany	4.4%
Italy	5.4%
United Kingdom	3.5%
France	5.0%

Russian Healthcare Companies Innovate in the Therapeutic Nuclear Medicine Industry

Through 2034, the therapeutic nuclear medicine industry in Russia is anticipated to register a 6.4% CAGR, owing to the development of prominent and emerging pharmaceutical and neurological research organizations.

In Russia, nuclear medicine is used to diagnose and treat various diseases, particularly cardiovascular and neurological conditions, but the key focus has always been placed on oncology.

Chronic Illnesses of German Populace Demands Radiopharmaceutical Therapies

The demand for these medicines is projected to report a CAGR of 4.4% in Germany by 2034 due to the prevalence of chronic diseases such as neuroendocrine tumors, prostate cancer, meningiomas, thyroid cancer, and lymphoma.

As therapeutic nuclear drugs are considered effective drugs for the treatment of cancer in the initial stages, thus German research and development organizations are developing novel radiopharmaceutical therapies.

Although therapeutic nuclear treatments’ future seems promising in the country, the German health regulatory bodies plummet the growth rate of radiopharmaceutical therapies.

Italian Geriatric Population Nurtures the Demand for Therapeutic Nuclear Medicine

The demand for these medicines in Italy is anticipated to showcase a CAGR of 5.4% between 2024 and 2034 as geriatric patients grow nationwide. The Italian medical environment targets the research and development of effective nuclear treatments that can aid in senior health.

French Healthcare Supports the Sales Growth of Therapeutic Nuclear Medicine

The demand for these medicines in France is projected to report a CAGR of 5.0% from 2024 to 2034, as the French field of nuclear medicine and theranostics is developing rapidly. France has over two hundred nuclear medicine departments that use radionuclides for diagnostic or therapeutic objectives in various domains such as oncology, cardiology, neurology, or endocrinology. The medical community is promoting therapeutic nuclear treatment in healthcare environments.

Climate Shift in the United Kingdom Promotes the Sales Growth of Nuclear Medicine Therapeutics

Sales of therapeutic nuclear medicines in the United Kingdom are set to witness a CAGR of 3.5% through 2034. Therapeutic nuclear medicine in the United Kingdom has developed fairly inconsistently over the last half-century.

Nonetheless, the regular climate shifts in the United Kingdom have created a prevalence of cardiovascular illnesses, necessitating the use of therapeutic nuclear medication. The rising geriatric population in the United Kingdom demands innovation in radioisotope therapies aiding in the treatment of prostate cancer.

Market Players Shaping the Outlook of the Therapeutic Nuclear Medicine Market

The therapeutic nuclear medicine industry’s dynamics are changing, and the key market players are vying for the majority stake in the competitive environment. Market players are implementing organic marketing techniques such as mergers and acquisitions, collaborations, and product launches to acquire a competitive advantage.

Top players produce the majority of nuclear medicine treatment products. Industry leaders have built their position in the market by investing more in research and having a better distribution system.

Recent technological developments in nuclear imaging modalities and the introduction of innovative pharmaceuticals into the global market have given the industry a huge boost. Continued and persistent research and development activities that result in betterment in new application areas are pushing market expansion.

Recent Developments in the Therapeutic Nuclear Medicine Market

In February 2024, The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held a Mid-Winter Meeting in Orlando, drawing over 700 professionals from various fields to learn from experts and enhance patient care.
In January 2024, The University of Texas MD Anderson Cancer Center partnered with the International Atomic Energy Agency (IAEA) to establish an IAEA Collaborating Centre, directing to improve global radiation oncology, radiation physics, radiology, nuclear medicine, and nutrition, focusing on healthcare.
In January 2024, BARC's Radiation Medicine Research Centre (RMRC) in Kolkata launched advanced Nuclear Medicine services, including FDG PET/CT imaging. The center aspires to provide affordable, advanced diagnostic and therapeutic services in India's Eastern and northeastern states while providing medical and science graduate training and R&D efforts in Nuclear Medicine imaging and radiopharmaceutical development.
In July 2023, The International BRICS Expert Forum on Nuclear Medicine in Moscow attracted over 200 representatives from Russia, Brazil, India, China, and South Africa to discuss progressions in radionuclide diagnostics, disease treatment, and medical device development.

Key Companies in the Therapeutic Nuclear Medicine Market

Bayer AG
GE Healthcare
Novartis AG
Cardinal Health Inc.
Mallinckrodt plc.
Lantheus Medical Imaging Inc.
Bracco Imaging S.p.A
Eckert & Ziegler
Curium Pharma
International Isotopes Idaho, Inc.
Medi-Radiopharma Co., Ltd.

Key Coverage in the Therapeutic Nuclear Medicine Market Report

Growth Analysis of Targeted Radionuclide Therapy in the United States
Growth Analysis of the Radiopharmaceutical Therapy Industry
Assessment of Emerging Trends in Therapeutic Nuclear Medicine
Overview of Therapeutic Nuclear Medicine Industry in the United States
Market Dynamics of Nuclear Medicine Therapeutics

Key Segments

By Treatment Type:

Radium-223
Iodine-131
Leutitium-177
Yttrium-90
Samarium-153
Strontium-89
Rhenium-188+Rhenium-186
Erbium- 169
Phosphorous-32
Others

By Indication:

Prostate Cancer
Painful Bone Metastases
Thyroid Cancer
Neuroblastoma
Synovitis
Non-Hodgkin’s Lymphoma
Hepatic Metastases
Brain Tumour
Others

By Distribution Channel:

Hospitals
Ambulatory Surgical Centers
Cancer Research Institutes

By Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa

Frequently Asked Questions

How Big is the Therapeutic Nuclear Medicine Market?

The market is set to be valued at US$ 1.32 billion in 2024.

What is the Therapeutic Nuclear Medicine Industry Supposed to be Worth in the Future?

The therapeutic nuclear medicine industry is anticipated to be valued at US$ 1.97 billion by 2034.

How Will the Therapeutic Nuclear Medicine Market Progress in the United Kingdom?

In the United Kingdom, demand is anticipated to develop at a CAGR of 3.5% by 2034.

Does Therapeutic Nuclear Medicine have a Future?

The therapeutic nuclear medicine industry is projected to register a CAGR of 4.10% from 2024 to 2034.

What are the Segments of the Therapeutic Nuclear Medicine Industry?

Therapeutic nuclear medicine industry has the following segments: treatment, indication, and distribution channel.

Table of Content

1. Executive Summary
    1.1. Global Market Outlook
    1.2. Demand-side Trends
    1.3. Supply-side Trends
    1.4. Technology Roadmap Analysis
    1.5. Analysis and Recommendations
2. Market Overview
    2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations
3. Market Background
    3.1. Market Dynamics
        3.1.1. Drivers
        3.1.2. Restraints
        3.1.3. Opportunity
        3.1.4. Trends
    3.2. Scenario Forecast
        3.2.1. Demand in Optimistic Scenario
        3.2.2. Demand in Likely Scenario
        3.2.3. Demand in Conservative Scenario
    3.3. Opportunity Map Analysis
    3.4. Product Life Cycle Analysis
    3.5. Supply Chain Analysis
        3.5.1. Supply Side Participants and their Roles
            3.5.1.1. Manufacturer
            3.5.1.2. Mid-Level Participants
            3.5.1.3. Distributors
        3.5.2. Value Added and Value Created at Node in the Supply Chain
        3.5.3. List of Raw Material Suppliers
        3.5.4. List of Existing and Potential Buyer’s
    3.6. Investment Feasibility Matrix
    3.7. Value Chain Analysis
        3.7.1. Profit Margin Analysis
        3.7.2. Distributors
    3.8. PESTLE and Porter’s Analysis
    3.9. Regulatory Landscape
        3.9.1. By Key Regions
        3.9.2. By Key Countries
    3.10. Regional Parent Market Outlook
    3.11. Production and Consumption Statistics
    3.12. Import and Export Statistics
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
    4.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis, 2019 to 2023
    4.2. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Projections, 2024 to 2034
        4.2.1. Y-o-Y Growth Trend Analysis
        4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Treatment
    5.1. Introduction / Key Findings
    5.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Treatment, 2019 to 2023
    5.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Treatment, 2024 to 2034
        5.3.1. Radium-223
        5.3.2. Iodine-131
        5.3.3. Leutitium-177
        5.3.4. Yttrium-90
        5.3.5. Samarium-153
        5.3.6. Strontium-89
        5.3.7. Rhenium-188+Rhenium-186
        5.3.8. Erbium-169
        5.3.9. Phosphorous-32
        5.3.10. Others
    5.4. Y-o-Y Growth Trend Analysis By Treatment, 2019 to 2023
    5.5. Absolute $ Opportunity Analysis By Treatment, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Indication
    6.1. Introduction / Key Findings
    6.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Indication, 2019 to 2023
    6.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Indication, 2024 to 2034
        6.3.1. Prostate Cancer
        6.3.2. Painful Bone Metastases
        6.3.3. Thyroid Cancer
        6.3.4. Neuroblastoma
        6.3.5. Synovitis
        6.3.6. Non-Hodgkin’s Lymphoma
        6.3.7. Hepatic Metastases
        6.3.8. Brain Tumour
        6.3.9. Others
    6.4. Y-o-Y Growth Trend Analysis By Indication, 2019 to 2023
    6.5. Absolute $ Opportunity Analysis By Indication, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
    7.1. Introduction / Key Findings
    7.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Distribution Channel, 2019 to 2023
    7.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Distribution Channel, 2024 to 2034
        7.3.1. Hospitals
        7.3.2. Ambulatory Surgical Centres
        7.3.3. Cancer Research Institutes
    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023
    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
    8.1. Introduction
    8.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Region, 2019 to 2023
    8.3. Current Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Region, 2024 to 2034
        8.3.1. North America
        8.3.2. Latin America
        8.3.3. Western Europe
        8.3.4. Eastern Europe
        8.3.5. South Asia and Pacific
        8.3.6. East Asia
        8.3.7. Middle East and Africa
    8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    9.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
    9.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
        9.2.1. By Country
            9.2.1.1. USA
            9.2.1.2. Canada
        9.2.2. By Treatment
        9.2.3. By Indication
        9.2.4. By Distribution Channel
    9.3. Market Attractiveness Analysis
        9.3.1. By Country
        9.3.2. By Treatment
        9.3.3. By Indication
        9.3.4. By Distribution Channel
    9.4. Key Takeaways
10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    10.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
    10.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
        10.2.1. By Country
            10.2.1.1. Brazil
            10.2.1.2. Mexico
            10.2.1.3. Rest of Latin America
        10.2.2. By Treatment
        10.2.3. By Indication
        10.2.4. By Distribution Channel
    10.3. Market Attractiveness Analysis
        10.3.1. By Country
        10.3.2. By Treatment
        10.3.3. By Indication
        10.3.4. By Distribution Channel
    10.4. Key Takeaways
11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    11.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
    11.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
        11.2.1. By Country
            11.2.1.1. Germany
            11.2.1.2. UK
            11.2.1.3. France
            11.2.1.4. Spain
            11.2.1.5. Italy
            11.2.1.6. Rest of Western Europe
        11.2.2. By Treatment
        11.2.3. By Indication
        11.2.4. By Distribution Channel
    11.3. Market Attractiveness Analysis
        11.3.1. By Country
        11.3.2. By Treatment
        11.3.3. By Indication
        11.3.4. By Distribution Channel
    11.4. Key Takeaways
12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    12.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
    12.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
        12.2.1. By Country
            12.2.1.1. Poland
            12.2.1.2. Russia
            12.2.1.3. Czech Republic
            12.2.1.4. Romania
            12.2.1.5. Rest of Eastern Europe
        12.2.2. By Treatment
        12.2.3. By Indication
        12.2.4. By Distribution Channel
    12.3. Market Attractiveness Analysis
        12.3.1. By Country
        12.3.2. By Treatment
        12.3.3. By Indication
        12.3.4. By Distribution Channel
    12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    13.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
    13.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
        13.2.1. By Country
            13.2.1.1. India
            13.2.1.2. Bangladesh
            13.2.1.3. Australia
            13.2.1.4. New Zealand
            13.2.1.5. Rest of South Asia and Pacific
        13.2.2. By Treatment
        13.2.3. By Indication
        13.2.4. By Distribution Channel
    13.3. Market Attractiveness Analysis
        13.3.1. By Country
        13.3.2. By Treatment
        13.3.3. By Indication
        13.3.4. By Distribution Channel
    13.4. Key Takeaways
14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    14.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
    14.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
        14.2.1. By Country
            14.2.1.1. China
            14.2.1.2. Japan
            14.2.1.3. South Korea
        14.2.2. By Treatment
        14.2.3. By Indication
        14.2.4. By Distribution Channel
    14.3. Market Attractiveness Analysis
        14.3.1. By Country
        14.3.2. By Treatment
        14.3.3. By Indication
        14.3.4. By Distribution Channel
    14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    15.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
    15.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
        15.2.1. By Country
            15.2.1.1. GCC Countries
            15.2.1.2. South Africa
            15.2.1.3. Israel
            15.2.1.4. Rest of MEA
        15.2.2. By Treatment
        15.2.3. By Indication
        15.2.4. By Distribution Channel
    15.3. Market Attractiveness Analysis
        15.3.1. By Country
        15.3.2. By Treatment
        15.3.3. By Indication
        15.3.4. By Distribution Channel
    15.4. Key Takeaways
16. Key Countries Market Analysis
    16.1. USA
        16.1.1. Pricing Analysis
        16.1.2. Market Share Analysis, 2023
            16.1.2.1. By Treatment
            16.1.2.2. By Indication
            16.1.2.3. By Distribution Channel
    16.2. Canada
        16.2.1. Pricing Analysis
        16.2.2. Market Share Analysis, 2023
            16.2.2.1. By Treatment
            16.2.2.2. By Indication
            16.2.2.3. By Distribution Channel
    16.3. Brazil
        16.3.1. Pricing Analysis
        16.3.2. Market Share Analysis, 2023
            16.3.2.1. By Treatment
            16.3.2.2. By Indication
            16.3.2.3. By Distribution Channel
    16.4. Mexico
        16.4.1. Pricing Analysis
        16.4.2. Market Share Analysis, 2023
            16.4.2.1. By Treatment
            16.4.2.2. By Indication
            16.4.2.3. By Distribution Channel
    16.5. Germany
        16.5.1. Pricing Analysis
        16.5.2. Market Share Analysis, 2023
            16.5.2.1. By Treatment
            16.5.2.2. By Indication
            16.5.2.3. By Distribution Channel
    16.6. UK
        16.6.1. Pricing Analysis
        16.6.2. Market Share Analysis, 2023
            16.6.2.1. By Treatment
            16.6.2.2. By Indication
            16.6.2.3. By Distribution Channel
    16.7. France
        16.7.1. Pricing Analysis
        16.7.2. Market Share Analysis, 2023
            16.7.2.1. By Treatment
            16.7.2.2. By Indication
            16.7.2.3. By Distribution Channel
    16.8. Spain
        16.8.1. Pricing Analysis
        16.8.2. Market Share Analysis, 2023
            16.8.2.1. By Treatment
            16.8.2.2. By Indication
            16.8.2.3. By Distribution Channel
    16.9. Italy
        16.9.1. Pricing Analysis
        16.9.2. Market Share Analysis, 2023
            16.9.2.1. By Treatment
            16.9.2.2. By Indication
            16.9.2.3. By Distribution Channel
    16.10. Poland
        16.10.1. Pricing Analysis
        16.10.2. Market Share Analysis, 2023
            16.10.2.1. By Treatment
            16.10.2.2. By Indication
            16.10.2.3. By Distribution Channel
    16.11. Russia
        16.11.1. Pricing Analysis
        16.11.2. Market Share Analysis, 2023
            16.11.2.1. By Treatment
            16.11.2.2. By Indication
            16.11.2.3. By Distribution Channel
    16.12. Czech Republic
        16.12.1. Pricing Analysis
        16.12.2. Market Share Analysis, 2023
            16.12.2.1. By Treatment
            16.12.2.2. By Indication
            16.12.2.3. By Distribution Channel
    16.13. Romania
        16.13.1. Pricing Analysis
        16.13.2. Market Share Analysis, 2023
            16.13.2.1. By Treatment
            16.13.2.2. By Indication
            16.13.2.3. By Distribution Channel
    16.14. India
        16.14.1. Pricing Analysis
        16.14.2. Market Share Analysis, 2023
            16.14.2.1. By Treatment
            16.14.2.2. By Indication
            16.14.2.3. By Distribution Channel
    16.15. Bangladesh
        16.15.1. Pricing Analysis
        16.15.2. Market Share Analysis, 2023
            16.15.2.1. By Treatment
            16.15.2.2. By Indication
            16.15.2.3. By Distribution Channel
    16.16. Australia
        16.16.1. Pricing Analysis
        16.16.2. Market Share Analysis, 2023
            16.16.2.1. By Treatment
            16.16.2.2. By Indication
            16.16.2.3. By Distribution Channel
    16.17. New Zealand
        16.17.1. Pricing Analysis
        16.17.2. Market Share Analysis, 2023
            16.17.2.1. By Treatment
            16.17.2.2. By Indication
            16.17.2.3. By Distribution Channel
    16.18. China
        16.18.1. Pricing Analysis
        16.18.2. Market Share Analysis, 2023
            16.18.2.1. By Treatment
            16.18.2.2. By Indication
            16.18.2.3. By Distribution Channel
    16.19. Japan
        16.19.1. Pricing Analysis
        16.19.2. Market Share Analysis, 2023
            16.19.2.1. By Treatment
            16.19.2.2. By Indication
            16.19.2.3. By Distribution Channel
    16.20. South Korea
        16.20.1. Pricing Analysis
        16.20.2. Market Share Analysis, 2023
            16.20.2.1. By Treatment
            16.20.2.2. By Indication
            16.20.2.3. By Distribution Channel
    16.21. GCC Countries
        16.21.1. Pricing Analysis
        16.21.2. Market Share Analysis, 2023
            16.21.2.1. By Treatment
            16.21.2.2. By Indication
            16.21.2.3. By Distribution Channel
    16.22. South Africa
        16.22.1. Pricing Analysis
        16.22.2. Market Share Analysis, 2023
            16.22.2.1. By Treatment
            16.22.2.2. By Indication
            16.22.2.3. By Distribution Channel
    16.23. Israel
        16.23.1. Pricing Analysis
        16.23.2. Market Share Analysis, 2023
            16.23.2.1. By Treatment
            16.23.2.2. By Indication
            16.23.2.3. By Distribution Channel
17. Market Structure Analysis
    17.1. Competition Dashboard
    17.2. Competition Benchmarking
    17.3. Market Share Analysis of Top Players
        17.3.1. By Regional
        17.3.2. By Treatment
        17.3.3. By Indication
        17.3.4. By Distribution Channel
18. Competition Analysis
    18.1. Competition Deep Dive
        18.1.1. Bayer AG
            18.1.1.1. Overview
            18.1.1.2. Product Portfolio
            18.1.1.3. Profitability by Market Segments
            18.1.1.4. Sales Footprint
            18.1.1.5. Strategy Overview
                18.1.1.5.1. Marketing Strategy
                18.1.1.5.2. Product Strategy
                18.1.1.5.3. Channel Strategy
        18.1.2. GE Healthcare
            18.1.2.1. Overview
            18.1.2.2. Product Portfolio
            18.1.2.3. Profitability by Market Segments
            18.1.2.4. Sales Footprint
            18.1.2.5. Strategy Overview
                18.1.2.5.1. Marketing Strategy
                18.1.2.5.2. Product Strategy
                18.1.2.5.3. Channel Strategy
        18.1.3. Novartis AG
            18.1.3.1. Overview
            18.1.3.2. Product Portfolio
            18.1.3.3. Profitability by Market Segments
            18.1.3.4. Sales Footprint
            18.1.3.5. Strategy Overview
                18.1.3.5.1. Marketing Strategy
                18.1.3.5.2. Product Strategy
                18.1.3.5.3. Channel Strategy
        18.1.4. Cardinal Health Inc.
            18.1.4.1. Overview
            18.1.4.2. Product Portfolio
            18.1.4.3. Profitability by Market Segments
            18.1.4.4. Sales Footprint
            18.1.4.5. Strategy Overview
                18.1.4.5.1. Marketing Strategy
                18.1.4.5.2. Product Strategy
                18.1.4.5.3. Channel Strategy
        18.1.5. Mallinckrodt plc.
            18.1.5.1. Overview
            18.1.5.2. Product Portfolio
            18.1.5.3. Profitability by Market Segments
            18.1.5.4. Sales Footprint
            18.1.5.5. Strategy Overview
                18.1.5.5.1. Marketing Strategy
                18.1.5.5.2. Product Strategy
                18.1.5.5.3. Channel Strategy
        18.1.6. Lantheus Medical Imaging Inc.
            18.1.6.1. Overview
            18.1.6.2. Product Portfolio
            18.1.6.3. Profitability by Market Segments
            18.1.6.4. Sales Footprint
            18.1.6.5. Strategy Overview
                18.1.6.5.1. Marketing Strategy
                18.1.6.5.2. Product Strategy
                18.1.6.5.3. Channel Strategy
        18.1.7. Bracco Imaging S.p.A
            18.1.7.1. Overview
            18.1.7.2. Product Portfolio
            18.1.7.3. Profitability by Market Segments
            18.1.7.4. Sales Footprint
            18.1.7.5. Strategy Overview
                18.1.7.5.1. Marketing Strategy
                18.1.7.5.2. Product Strategy
                18.1.7.5.3. Channel Strategy
        18.1.8. Eckert & Ziegler
            18.1.8.1. Overview
            18.1.8.2. Product Portfolio
            18.1.8.3. Profitability by Market Segments
            18.1.8.4. Sales Footprint
            18.1.8.5. Strategy Overview
                18.1.8.5.1. Marketing Strategy
                18.1.8.5.2. Product Strategy
                18.1.8.5.3. Channel Strategy
        18.1.9. Curium Pharma
            18.1.9.1. Overview
            18.1.9.2. Product Portfolio
            18.1.9.3. Profitability by Market Segments
            18.1.9.4. Sales Footprint
            18.1.9.5. Strategy Overview
                18.1.9.5.1. Marketing Strategy
                18.1.9.5.2. Product Strategy
                18.1.9.5.3. Channel Strategy
        18.1.10. International Isotopes Idaho, Inc.
            18.1.10.1. Overview
            18.1.10.2. Product Portfolio
            18.1.10.3. Profitability by Market Segments
            18.1.10.4. Sales Footprint
            18.1.10.5. Strategy Overview
                18.1.10.5.1. Marketing Strategy
                18.1.10.5.2. Product Strategy
                18.1.10.5.3. Channel Strategy
        18.1.11. Medi-Radiopharma Co., Ltd.
            18.1.11.1. Overview
            18.1.11.2. Product Portfolio
            18.1.11.3. Profitability by Market Segments
            18.1.11.4. Sales Footprint
            18.1.11.5. Strategy Overview
                18.1.11.5.1. Marketing Strategy
                18.1.11.5.2. Product Strategy
                18.1.11.5.3. Channel Strategy
19. Assumptions & Acronyms Used
20. Research Methodology

Therapeutic Nuclear Medicine Market

Therapeutic Nuclear Medicine Market Forecast by Prostate Cancer and Thyroid Cancer for 2024 to 2034